Effect of Perfluorooctanesulfonic acid (PFOS) on immune cell development and function in mice.
Alkanesulfonic Acids
/ pharmacology
Animals
Antibodies, Viral
/ blood
Biomarkers
Bone Marrow
/ drug effects
Cell Differentiation
/ drug effects
Female
Fluorocarbons
/ pharmacology
Granulocytes
/ cytology
Immunologic Factors
/ pharmacology
Immunophenotyping
Influenza A virus
/ immunology
Lymphocytes
/ cytology
Male
Mice
Organ Specificity
Orthomyxoviridae Infections
/ immunology
Spleen
/ cytology
Thymus Gland
/ immunology
Immune system
Influenza
PFOS
Journal
Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
22
04
2020
revised:
17
02
2021
accepted:
10
03
2021
pubmed:
17
3
2021
medline:
1
2
2022
entrez:
16
3
2021
Statut:
ppublish
Résumé
Perfluoroctanesulfonate (PFOS) belongs to a larger family of compounds known as Per- and polyfluoroalkyl substances (PFAS). The strength of the carbon-fluorine bond makes PFOS extremely resistant to environmental degradation. Due to its persistent nature, research has been directed to elucidating possible health effects of PFOS on humans and laboratory animals. Here we have explored the effects of PFOS exposure on immune development and function in mice. We exposed adult mice to 3 and 1.5 μg/kg/day of PFOS for 2 and 4 weeks, respectively, and examined the effects of PFOS exposure on populations of T cells, B cells, and granulocytes. These doses of PFOS resulted in serum levels of approximately 100 ng/mL with no weight loss during exposure. We find that PFOS does not affect T-cell development during this time. However, while PFOS exposure reduced immune cell populations in some organs, it also led to an increase in the numbers of cells in others, suggesting possible relocalization of cells. We also examined the effect of PFOS on the response to influenza virus infection. We find that exposure to PFOS at 1.5 μg/kg/day of PFOS for 4 weeks does not affect weight loss or survival, nor is viral clearance affected. Analysis of antibody and T cell specific antiviral responses indicate that at this concentration, PFOS does not suppress the immune cell development or antigen specific immune response.
Identifiants
pubmed: 33722553
pii: S0165-2478(21)00044-4
doi: 10.1016/j.imlet.2021.03.006
pmc: PMC8577040
mid: NIHMS1683185
pii:
doi:
Substances chimiques
Alkanesulfonic Acids
0
Antibodies, Viral
0
Biomarkers
0
Fluorocarbons
0
Immunologic Factors
0
perfluorooctane sulfonic acid
9H2MAI21CL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-41Subventions
Organisme : NIGMS NIH HHS
ID : R25 GM125597
Pays : United States
Informations de copyright
Copyright © 2021 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Références
Crit Rev Toxicol. 2017 Jul;47(6):482-508
pubmed: 28617200
Food Chem Toxicol. 2012 Sep;50(9):2955-63
pubmed: 22732150
Environ Sci Technol. 2006 Aug 15;40(16):4943-8
pubmed: 16955890
J Immunol. 2003 Jan 1;170(1):123-31
pubmed: 12496391
Toxicol Sci. 2017 Apr 1;156(2):387-401
pubmed: 28115654
J Vis Exp. 2018 Feb 28;(132):
pubmed: 29553537
Occup Environ Med. 2018 Jan;75(1):46-51
pubmed: 29133598
Integr Environ Assess Manag. 2011 Oct;7(4):513-41
pubmed: 21793199
Crit Rev Toxicol. 2016;46(4):279-331
pubmed: 26761418
Arch Toxicol. 2011 Oct;85(10):1235-44
pubmed: 21327619
PLoS One. 2009;4(3):e4857
pubmed: 19293935
EFSA J. 2018 Dec 13;16(12):e05194
pubmed: 32625773
J Toxicol Environ Health A. 2008;71(23):1516-25
pubmed: 18923994
J Toxicol Sci. 2009 Dec;34(6):687-91
pubmed: 19952504
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):148-156
pubmed: 30482935
Toxicol Lett. 2013 Feb 13;217(1):67-74
pubmed: 23237827
Environ Health. 2015 Jul 07;14:59
pubmed: 26148742
J Environ Sci Health A Tox Hazard Subst Environ Eng. 2011;46(2):97-108
pubmed: 21170772
Environ Health Perspect. 2007 Sep;115(9):1298-305
pubmed: 17805419
Chem Biol Interact. 2015 Oct 5;240:84-93
pubmed: 26300304
Int Immunopharmacol. 2010 Nov;10(11):1420-7
pubmed: 20816993
Int Immunopharmacol. 2001 Mar;1(3):507-20
pubmed: 11367534
Toxicology. 2009 Jun 16;260(1-3):68-76
pubmed: 19464571
Arch Toxicol. 2009 Sep;83(9):805-15
pubmed: 19343326
J Immunotoxicol. 2011 Jan-Mar;8(1):30-8
pubmed: 21299352
Viruses. 2010;2(8):1530-1563
pubmed: 21442033
Methods Mol Biol. 2014;1161:11-25
pubmed: 24899416
Arch Toxicol. 2009 Jul;83(7):679-89
pubmed: 19015834
Toxicology. 2010 Jan 12;267(1-3):132-9
pubmed: 19900501
Toxicol Sci. 2008 Jul;104(1):144-54
pubmed: 18359764
Toxicology. 2009 Aug 21;262(3):207-14
pubmed: 19540903
J Immunol. 2001 Dec 15;167(12):6983-90
pubmed: 11739518
Environ Res. 2007 Feb;103(2):176-84
pubmed: 16893538
Virology. 2005 Sep 30;340(2):296-306
pubmed: 16054188
Toxicology. 2011 Jun 18;284(1-3):54-62
pubmed: 21459123
Environ Int. 2017 Feb;99:15-28
pubmed: 27884404
Sci Rep. 2017 Jul 12;7(1):5166
pubmed: 28701769
Environ Health Perspect. 2015 Dec;123(12):1317-24
pubmed: 26008903
J Immunol. 2002 May 1;168(9):4455-61
pubmed: 11970989
Reprod Toxicol. 2012 Jul;33(4):428-440
pubmed: 21889587
Chemosphere. 2010 Jul;80(6):613-8
pubmed: 20493513
Toxicol Sci. 2008 May;103(1):77-85
pubmed: 18252804
Adv Exp Med Biol. 1988;245:203-8
pubmed: 3067553